APO Research
Talk to an analyst

APO RESEARCH · REPORT

Radiopharmaceutical (Oral Route)

Compare research editions
View pricing & licenses

Selected research

Market Structure

Global Radiopharmaceutical (Oral Route) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032

31 December 2025191 pages

Choose your research edition.

Industry ResearchRadiopharmaceutical (Oral Route) Industry Research Report 2026134 pages · $2,950 USDIndustry Growth & TrendsGlobal Radiopharmaceutical (Oral Route) Industry Growth and Trends Forecast to 2032114 pages · $3,450 USDMarket StructureGlobal Radiopharmaceutical (Oral Route) Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032191 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Radiopharmaceutical (Oral Route) Market Outlook and Growth Opportunities 2026197 pages · $4,250 USDMarket Analysis & ForecastGlobal Radiopharmaceutical (Oral Route) Market Analysis and Forecast 2026-2032194 pages · $4,950 USD

Market perspective

The global Radiopharmaceutical (Oral Route) market is projected to grow from US$ million in 2026 to US$ million by 2032, implying a CAGR of % over 2026-2032.

The US & Canada market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The China market for Radiopharmaceutical (Oral Route) is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Leading global manufacturers of Radiopharmaceutical (Oral Route) include Eli Lilly, Bayer, Triad Isotopes, SIEMENS, Nordion, Navidea, Mallinckrodt, Lantheus and Jubilant Pharma, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global Radiopharmaceutical (Oral Route) market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of Radiopharmaceutical (Oral Route) and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents Radiopharmaceutical (Oral Route) sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the Radiopharmaceutical (Oral Route) market size, projected growth trends, production technologies, key applications, and end-use industries.

Radiopharmaceutical (Oral Route) Segment by Company

Eli Lilly

Bayer

Triad Isotopes

SIEMENS

Nordion

Navidea

Mallinckrodt

Lantheus

Jubilant Pharma

IBA Group

GE Healthcare

Dongcheng

China Isotope & Radiation

Bracco Imaging

Advanced Accelerator Applications

Radiopharmaceutical (Oral Route) Segment by Type

Actinium-225

Holmium-166

Radium-223

Lutetium-177

Other

Radiopharmaceutical (Oral Route) Segment by Application

Oncology

Cardiology

Other

Radiopharmaceutical (Oral Route) Segment by Region

North America

United States

Canada

Europe

v

France

U.K.

Italy

Netherlands

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving, production, value, consumption, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, capacity, production, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Radiopharmaceutical (Oral Route) market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Radiopharmaceutical (Oral Route) and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Radiopharmaceutical (Oral Route).

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the Radiopharmaceutical (Oral Route) market, including product definition, global market growth prospects, market size, sales, and average price forecasts (2021-2032).

Chapter 2: Provides the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Detailed analysis of Radiopharmaceutical (Oral Route) manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales of Radiopharmaceutical (Oral Route) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 7: Revenue of Radiopharmaceutical (Oral Route) in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space of each country in the world.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights of the report

More report detail

Tables and figures
List of Tables Table 1. Radiopharmaceutical (Oral Route) Industry Trends Table 2. Radiopharmaceutical (Oral Route) Industry Drivers Table 3. Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges Table 4. Radiopharmaceutical (Oral Route) Industry Restraints Table 5. Global Radiopharmaceutical (Oral Route) Revenue by Manufacturers (US$ Million) & (2021-2026) Table 6. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Manufacturers (2021-2026) Table 7. Global Radiopharmaceutical (Oral Route) Sales by Manufacturers (K Units) & (2021-2026) Table 8. Global Radiopharmaceutical (Oral Route) Sales Market Share by Manufacturers Table 9. Global Radiopharmaceutical (Oral Route) Average Sales Price (US$/Unit) of Manufacturers (2021-2026) Table 10. Global Radiopharmaceutical (Oral Route) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026 Table 11. Global Radiopharmaceutical (Oral Route) Key Manufacturers Manufacturing Sites & Headquarters Table 12. Global Radiopharmaceutical (Oral Route) Manufacturers, Product Type & Application Table 13. Global Radiopharmaceutical (Oral Route) Manufacturers Establishment Date Table 14. Global Manufacturers Market Concentration Ratio (CR5 and HHI) Table 15. Global Radiopharmaceutical (Oral Route) by Manufacturers Type (Tier 1, Tier 2, and Tier 3) & (based on the Revenue of 2025) Table 16. Major Manufacturers of Actinium-225 Table 17. Major Manufacturers of Holmium-166 Table 18. Major Manufacturers of Radium-223 Table 19. Major Manufacturers of Lutetium-177 Table 20. Major Manufacturers of Other Table 21. Global Radiopharmaceutical (Oral Route) Sales by Type 2021 VS 2025 VS 2032 (K Units) Table 22. Global Radiopharmaceutical (Oral Route) Sales by Type (2021-2026) & (K Units) Table 23. Global Radiopharmaceutical (Oral Route) Sales by Type (2027-2032) & (K Units) Table 24. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2021-2026) Table 25. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2027-2032) Table 26. Global Radiopharmaceutical (Oral Route) Revenue by Type 2021 VS 2025 VS 2032 (K Units) Table 27. Global Radiopharmaceutical (Oral Route) Revenue by Type (2021-2026) & (K Units) Table 28. Global Radiopharmaceutical (Oral Route) Revenue by Type (2027-2032) & (K Units) Table 29. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2021-2026) Table 30. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2027-2032) Table 31. Major Manufacturers of Oncology Table 32. Major Manufacturers of Cardiology Table 33. Major Manufacturers of Other Table 34. Global Radiopharmaceutical (Oral Route) Sales by Application 2021 VS 2025 VS 2032 (K Units) Table 35. Global Radiopharmaceutical (Oral Route) Sales by Application (2021-2026) & (K Units) Table 36. Global Radiopharmaceutical (Oral Route) Sales by Application (2027-2032) & (K Units) Table 37. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2021-2026) Table 38. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2027-2032) Table 39. Global Radiopharmaceutical (Oral Route) Revenue by Application 2021 VS 2025 VS 2032 (K Units) Table 40. Global Radiopharmaceutical (Oral Route) Revenue by Application (2021-2026) & (K Units) Table 41. Global Radiopharmaceutical (Oral Route) Revenue by Application (2027-2032) & (K Units) Table 42. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2021-2026) Table 43. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2027-2032) Table 44. Global Radiopharmaceutical (Oral Route) Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 45. Global Radiopharmaceutical (Oral Route) Sales by Region (2021-2026) & (K Units) Table 46. Global Radiopharmaceutical (Oral Route) Sales Market Share by Region (2021-2026) Table 47. Global Radiopharmaceutical (Oral Route) Sales Forecasted by Region (2027-2032) & (K Units) Table 48. Global Radiopharmaceutical (Oral Route) Sales Forecasted Market Share by Region (2027-2032) Table 49. North America Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 50. North America Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 51. North America Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 52. Europe Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 53. Europe Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 54. Europe Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 55. Asia Pacific Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 56. Asia Pacific Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 57. Asia Pacific Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 58. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032 (K Units) Table 59. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2021-2026) & (K Units) Table 60. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2027-2032) & (K Units) Table 61. Global Radiopharmaceutical (Oral Route) Revenue Grow Rate (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 62. Global Radiopharmaceutical (Oral Route) Revenue by Region (2021-2026) & (US$ Million) Table 63. Global Radiopharmaceutical (Oral Route) Revenue by Region (2027-2032) & (US$ Million) Table 64. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2021-2026) Table 65. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2027-2032) Table 66. Eli Lilly Company Information Table 67. Eli Lilly Business Overview Table 68. Eli Lilly Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 69. Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio Table 70. Eli Lilly Recent Development Table 71. Bayer Company Information Table 72. Bayer Business Overview Table 73. Bayer Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 74. Bayer Radiopharmaceutical (Oral Route) Product Portfolio Table 75. Bayer Recent Development Table 76. Triad Isotopes Company Information Table 77. Triad Isotopes Business Overview Table 78. Triad Isotopes Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 79. Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio Table 80. Triad Isotopes Recent Development Table 81. SIEMENS Company Information Table 82. SIEMENS Business Overview Table 83. SIEMENS Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 84. SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio Table 85. SIEMENS Recent Development Table 86. Nordion Company Information Table 87. Nordion Business Overview Table 88. Nordion Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 89. Nordion Radiopharmaceutical (Oral Route) Product Portfolio Table 90. Nordion Recent Development Table 91. Navidea Company Information Table 92. Navidea Business Overview Table 93. Navidea Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 94. Navidea Radiopharmaceutical (Oral Route) Product Portfolio Table 95. Navidea Recent Development Table 96. Mallinckrodt Company Information Table 97. Mallinckrodt Business Overview Table 98. Mallinckrodt Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 99. Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio Table 100. Mallinckrodt Recent Development Table 101. Lantheus Company Information Table 102. Lantheus Business Overview Table 103. Lantheus Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 104. Lantheus Radiopharmaceutical (Oral Route) Product Portfolio Table 105. Lantheus Recent Development Table 106. Jubilant Pharma Company Information Table 107. Jubilant Pharma Business Overview Table 108. Jubilant Pharma Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 109. Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio Table 110. Jubilant Pharma Recent Development Table 111. IBA Group Company Information Table 112. IBA Group Business Overview Table 113. IBA Group Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 114. IBA Group Radiopharmaceutical (Oral Route) Product Portfolio Table 115. IBA Group Recent Development Table 116. GE Healthcare Company Information Table 117. GE Healthcare Business Overview Table 118. GE Healthcare Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 119. GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio Table 120. GE Healthcare Recent Development Table 121. Dongcheng Company Information Table 122. Dongcheng Business Overview Table 123. Dongcheng Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 124. Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio Table 125. Dongcheng Recent Development Table 126. China Isotope & Radiation Company Information Table 127. China Isotope & Radiation Business Overview Table 128. China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 129. China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio Table 130. China Isotope & Radiation Recent Development Table 131. Bracco Imaging Company Information Table 132. Bracco Imaging Business Overview Table 133. Bracco Imaging Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 134. Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio Table 135. Bracco Imaging Recent Development Table 136. Advanced Accelerator Applications Company Information Table 137. Advanced Accelerator Applications Business Overview Table 138. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales (K Units), Price (US$/Unit), Revenue (US$ Million) and Gross Margin (2021-2026) Table 139. Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio Table 140. Advanced Accelerator Applications Recent Development Table 141. Key Raw Materials Table 142. Raw Materials Key Suppliers Table 143. Radiopharmaceutical (Oral Route) Distributors List Table 144. Radiopharmaceutical (Oral Route) Customers List Table 145. Research Programs/Design for This Report Table 146. Authors List of This Report Table 147. Secondary Sources Table 148. Primary Sources List of Figures Figure 1. Radiopharmaceutical (Oral Route) Product Image Figure 2. Global Radiopharmaceutical (Oral Route) Market Size (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Radiopharmaceutical (Oral Route) Market Size (2021-2032) & (US$ Million) Figure 4. Global Radiopharmaceutical (Oral Route) Sales (2021-2032) & (K Units) Figure 5. Global Radiopharmaceutical (Oral Route) Average Price (US$/Unit) & (2021-2032) Figure 6. Global Top 5 and 10 Radiopharmaceutical (Oral Route) Players Market Share by Revenue in 2025 Figure 7. Manufacturers Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 8. Actinium-225 Image Figure 9. Holmium-166 Image Figure 10. Radium-223 Image Figure 11. Lutetium-177 Image Figure 12. Other Image Figure 13. Global Radiopharmaceutical (Oral Route) Sales by Type (2021 VS 2025 VS 2032) & (K Units) Figure 14. Global Radiopharmaceutical (Oral Route) Sales Market Share 2021 VS 2025 VS 2032 Figure 15. Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2021-2032) Figure 16. Global Radiopharmaceutical (Oral Route) Revenue by Type (2021 VS 2025 VS 2032) & (K Units) Figure 17. Global Radiopharmaceutical (Oral Route) Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2021-2032) Figure 19. Oncology Image Figure 20. Cardiology Image Figure 21. Other Image Figure 22. Global Radiopharmaceutical (Oral Route) Sales by Application (2021 VS 2025 VS 2032) & (K Units) Figure 23. Global Radiopharmaceutical (Oral Route) Sales Market Share 2021 VS 2025 VS 2032 Figure 24. Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2021-2032) Figure 25. Global Radiopharmaceutical (Oral Route) Revenue by Application (2021 VS 2025 VS 2032) & (K Units) Figure 26. Global Radiopharmaceutical (Oral Route) Revenue Market Share 2021 VS 2025 VS 2032 Figure 27. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2021-2032) Figure 28. North America Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 29. North America Radiopharmaceutical (Oral Route) Sales Market Share by Country (2021-2032) Figure 30. U.S. Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 31. Canada Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 32. Mexico Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 33. Europe Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 34. Europe Radiopharmaceutical (Oral Route) Sales Market Share by Country (2021-2032) Figure 35. Germany Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 36. France Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 37. U.K. Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 38. Italy Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 39. Netherlands Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 40. Asia Pacific Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 41. Asia Pacific Radiopharmaceutical (Oral Route) Sales Market Share by Country (2021-2032) Figure 42. China Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 43. Japan Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 44. South Korea Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 45. Southeast Asia Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 46. India Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 47. Australia Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 48. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 49. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales Market Share by Country (2021-2032) Figure 50. Brazil Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 51. South Africa Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 52. Saudi Arabia Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 53. Turkey Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 54. Argentina Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 55. UAE Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 56. Egypt Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 57. Chile Radiopharmaceutical (Oral Route) Sales and Growth Rate (2021-2032) & (K Units) Figure 58. Global Radiopharmaceutical (Oral Route) Revenue (CAGR) by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 59. Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region in Percentage: 2025 Versus 2032 Figure 60. North America Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Figure 61. North America Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 62. Europe Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Figure 63. Europe Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 64. Asia-Pacific Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Figure 65. Asia-Pacific Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 66. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Revenue (2021-2032) & (US$ Million) Figure 67. South America, Middle East and Africa Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032 Figure 68. Radiopharmaceutical (Oral Route) Value Chain Figure 69. Manufacturing Cost Structure Figure 70. Radiopharmaceutical (Oral Route) Production Mode & Process Figure 71. Direct Comparison with Distribution Share Figure 72. Distributors Profiles Figure 73. Years Considered Figure 74. Research Process Figure 75. Key Executives Interviewed

Scope & coverage.

Types
  • Actinium-225
  • Holmium-166
  • Radium-223
  • Lutetium-177
  • Other
Applications
  • Oncology
  • Cardiology
  • Other
Companies covered
  • Eli Lilly
  • Bayer
  • Triad Isotopes
  • SIEMENS
  • Nordion
  • Navidea
  • Mallinckrodt
  • Lantheus
  • Jubilant Pharma
  • IBA Group
  • GE Healthcare
  • Dongcheng
  • China Isotope & Radiation
  • Bracco Imaging
  • Advanced Accelerator Applications

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Radiopharmaceutical (Oral Route) Market Size, 2021 VS 2025 VS 2032
  3. 1.3 Global Radiopharmaceutical (Oral Route) Market Size Estimates and Forecasts (2021-2032)
  4. 1.4 Global Radiopharmaceutical (Oral Route) Sales Estimates and Forecasts (2021-2032)
  5. 1.5 Global Radiopharmaceutical (Oral Route) Market Average Price (2021-2032)
  6. 1.6 Assumptions and Limitations
  7. 1.7 Study Goals and Objectives
2 Global Radiopharmaceutical (Oral Route) Market Dynamics
  1. 2.1 Radiopharmaceutical (Oral Route) Industry Trends
  2. 2.2 Radiopharmaceutical (Oral Route) Industry Drivers
  3. 2.3 Radiopharmaceutical (Oral Route) Industry Opportunities and Challenges
  4. 2.4 Radiopharmaceutical (Oral Route) Industry Restraints
3 Radiopharmaceutical (Oral Route) Market by Manufacturers
  1. 3.1 Global Radiopharmaceutical (Oral Route) Revenue by Manufacturers (2021-2026)
  2. 3.2 Global Radiopharmaceutical (Oral Route) Sales by Manufacturers (2021-2026)
  3. 3.3 Global Radiopharmaceutical (Oral Route) Average Sales Price by Manufacturers (2021-2026)
  4. 3.4 Global Radiopharmaceutical (Oral Route) Industry Manufacturers Ranking, 2024 VS 2025 VS 2026
  5. 3.5 Global Radiopharmaceutical (Oral Route) Key Manufacturers Manufacturing Sites & Headquarters
  6. 3.6 Global Radiopharmaceutical (Oral Route) Manufacturers, Product Type & Application
  7. 3.7 Global Radiopharmaceutical (Oral Route) Manufacturers Establishment Date
  8. 3.8 Market Competitive Analysis
  9. 3.8.1 Global Radiopharmaceutical (Oral Route) Market CR5 and HHI
  10. 3.8.2 Global Top 5 and 10 Radiopharmaceutical (Oral Route) Players Market Share by Revenue in 2025
  11. 3.8.3 2025 Radiopharmaceutical (Oral Route) Tier 1, Tier 2, and Tier 3
4 Radiopharmaceutical (Oral Route) Market by Type
  1. 4.1 Radiopharmaceutical (Oral Route) Type Introduction
  2. 4.1.1 Actinium-225
  3. 4.1.2 Holmium-166
  4. 4.1.3 Radium-223
  5. 4.1.4 Lutetium-177
  6. 4.1.5 Other
  7. 4.2 Global Radiopharmaceutical (Oral Route) Sales by Type
  8. 4.2.1 Global Radiopharmaceutical (Oral Route) Sales by Type (2021 VS 2025 VS 2032)
  9. 4.2.2 Global Radiopharmaceutical (Oral Route) Sales by Type (2021-2032)
  10. 4.2.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Type (2021-2032)
  11. 4.3 Global Radiopharmaceutical (Oral Route) Revenue by Type
  12. 4.3.1 Global Radiopharmaceutical (Oral Route) Revenue by Type (2021 VS 2025 VS 2032)
  13. 4.3.2 Global Radiopharmaceutical (Oral Route) Revenue by Type (2021-2032)
  14. 4.3.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Type (2021-2032)
5 Radiopharmaceutical (Oral Route) Market by Application
  1. 5.1 Radiopharmaceutical (Oral Route) Application Introduction
  2. 5.1.1 Oncology
  3. 5.1.2 Cardiology
  4. 5.1.3 Other
  5. 5.2 Global Radiopharmaceutical (Oral Route) Sales by Application
  6. 5.2.1 Global Radiopharmaceutical (Oral Route) Sales by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global Radiopharmaceutical (Oral Route) Sales by Application (2021-2032)
  8. 5.2.3 Global Radiopharmaceutical (Oral Route) Sales Market Share by Application (2021-2032)
  9. 5.3 Global Radiopharmaceutical (Oral Route) Revenue by Application
  10. 5.3.1 Global Radiopharmaceutical (Oral Route) Revenue by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global Radiopharmaceutical (Oral Route) Revenue by Application (2021-2032)
  12. 5.3.3 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Application (2021-2032)
6 Global Radiopharmaceutical (Oral Route) Sales by Region
  1. 6.1 Global Radiopharmaceutical (Oral Route) Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global Radiopharmaceutical (Oral Route) Sales by Region (2021-2032)
  3. 6.2.1 Global Radiopharmaceutical (Oral Route) Sales by Region (2021-2026)
  4. 6.2.2 Global Radiopharmaceutical (Oral Route) Sales Forecasted by Region (2027-2032)
  5. 6.3 North America
  6. 6.3.1 North America Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  7. 6.3.2 North America Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
  8. 6.3.3 U.S.
  9. 6.3.4 Canada
  10. 6.3.5 Mexico
  11. 6.4 Europe
  12. 6.4.1 Europe Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  13. 6.4.2 Europe Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
  14. 6.4.3 Germany
  15. 6.4.4 France
  16. 6.4.5 U.K.
  17. 6.4.6 Italy
  18. 6.4.7 Netherlands
  19. 6.5 Asia Pacific
  20. 6.5.1 Asia Pacific Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  21. 6.5.2 Asia Pacific Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
  22. 6.5.3 China
  23. 6.5.4 Japan
  24. 6.5.5 South Korea
  25. 6.5.6 Southeast Asia
  26. 6.5.7 India
  27. 6.5.8 Australia
  28. 6.6 South America, Middle East and Africa
  29. 6.6.1 South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales Growth Rate by Country: 2021 VS 2025 VS 2032
  30. 6.6.2 South America, Middle East and Africa Radiopharmaceutical (Oral Route) Sales by Country (2021-2032)
  31. 6.6.3 Brazil
  32. 6.6.4 South Africa
  33. 6.6.5 Saudi Arabia
  34. 6.6.6 Turkey
  35. 6.6.6 Argentina
  36. 6.6.6 UAE
  37. 6.6.6 Egypt
  38. 6.6.6 Chile
7 Global Radiopharmaceutical (Oral Route) Revenue by Region
  1. 7.1 Global Radiopharmaceutical (Oral Route) Revenue by Region
  2. 7.1.1 Global Radiopharmaceutical (Oral Route) Revenue by Region: 2021 VS 2025 VS 2032
  3. 7.1.2 Global Radiopharmaceutical (Oral Route) Revenue by Region (2021-2026)
  4. 7.1.3 Global Radiopharmaceutical (Oral Route) Revenue by Region (2027-2032)
  5. 7.1.4 Global Radiopharmaceutical (Oral Route) Revenue Market Share by Region (2021-2032)
  6. 7.2 North America
  7. 7.2.1 North America Radiopharmaceutical (Oral Route) Revenue (2021-2032)
  8. 7.2.2 North America Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032
  9. 7.3 Europe
  10. 7.3.1 Europe Radiopharmaceutical (Oral Route) Revenue (2021-2032)
  11. 7.3.2 Europe Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032
  12. 7.4 Asia-Pacific
  13. 7.4.1 Asia-Pacific Radiopharmaceutical (Oral Route) Revenue (2021-2032)
  14. 7.4.2 Asia-Pacific Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032
  15. 7.5 South America, Middle East and Africa
  16. 7.5.1 South America, Middle East and Africa Radiopharmaceutical (Oral Route) Revenue (2021-2032)
  17. 7.5.2 South America, Middle East and Africa Radiopharmaceutical (Oral Route) Revenue Share by Country: 2021 VS 2025 VS 2032
8 Company Profiles
  1. 8.1 Eli Lilly
  2. 8.1.1 Eli Lilly Company Information
  3. 8.1.2 Eli Lilly Business Overview
  4. 8.1.3 Eli Lilly Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  5. 8.1.4 Eli Lilly Radiopharmaceutical (Oral Route) Product Portfolio
  6. 8.1.5 Eli Lilly Recent Developments
  7. 8.2 Bayer
  8. 8.2.1 Bayer Company Information
  9. 8.2.2 Bayer Business Overview
  10. 8.2.3 Bayer Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  11. 8.2.4 Bayer Radiopharmaceutical (Oral Route) Product Portfolio
  12. 8.2.5 Bayer Recent Developments
  13. 8.3 Triad Isotopes
  14. 8.3.1 Triad Isotopes Company Information
  15. 8.3.2 Triad Isotopes Business Overview
  16. 8.3.3 Triad Isotopes Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  17. 8.3.4 Triad Isotopes Radiopharmaceutical (Oral Route) Product Portfolio
  18. 8.3.5 Triad Isotopes Recent Developments
  19. 8.4 SIEMENS
  20. 8.4.1 SIEMENS Company Information
  21. 8.4.2 SIEMENS Business Overview
  22. 8.4.3 SIEMENS Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  23. 8.4.4 SIEMENS Radiopharmaceutical (Oral Route) Product Portfolio
  24. 8.4.5 SIEMENS Recent Developments
  25. 8.5 Nordion
  26. 8.5.1 Nordion Company Information
  27. 8.5.2 Nordion Business Overview
  28. 8.5.3 Nordion Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  29. 8.5.4 Nordion Radiopharmaceutical (Oral Route) Product Portfolio
  30. 8.5.5 Nordion Recent Developments
  31. 8.6 Navidea
  32. 8.6.1 Navidea Company Information
  33. 8.6.2 Navidea Business Overview
  34. 8.6.3 Navidea Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  35. 8.6.4 Navidea Radiopharmaceutical (Oral Route) Product Portfolio
  36. 8.6.5 Navidea Recent Developments
  37. 8.7 Mallinckrodt
  38. 8.7.1 Mallinckrodt Company Information
  39. 8.7.2 Mallinckrodt Business Overview
  40. 8.7.3 Mallinckrodt Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  41. 8.7.4 Mallinckrodt Radiopharmaceutical (Oral Route) Product Portfolio
  42. 8.7.5 Mallinckrodt Recent Developments
  43. 8.8 Lantheus
  44. 8.8.1 Lantheus Company Information
  45. 8.8.2 Lantheus Business Overview
  46. 8.8.3 Lantheus Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  47. 8.8.4 Lantheus Radiopharmaceutical (Oral Route) Product Portfolio
  48. 8.8.5 Lantheus Recent Developments
  49. 8.9 Jubilant Pharma
  50. 8.9.1 Jubilant Pharma Company Information
  51. 8.9.2 Jubilant Pharma Business Overview
  52. 8.9.3 Jubilant Pharma Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  53. 8.9.4 Jubilant Pharma Radiopharmaceutical (Oral Route) Product Portfolio
  54. 8.9.5 Jubilant Pharma Recent Developments
  55. 8.10 IBA Group
  56. 8.10.1 IBA Group Company Information
  57. 8.10.2 IBA Group Business Overview
  58. 8.10.3 IBA Group Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  59. 8.10.4 IBA Group Radiopharmaceutical (Oral Route) Product Portfolio
  60. 8.10.5 IBA Group Recent Developments
  61. 8.11 GE Healthcare
  62. 8.11.1 GE Healthcare Company Information
  63. 8.11.2 GE Healthcare Business Overview
  64. 8.11.3 GE Healthcare Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  65. 8.11.4 GE Healthcare Radiopharmaceutical (Oral Route) Product Portfolio
  66. 8.11.5 GE Healthcare Recent Developments
  67. 8.12 Dongcheng
  68. 8.12.1 Dongcheng Company Information
  69. 8.12.2 Dongcheng Business Overview
  70. 8.12.3 Dongcheng Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  71. 8.12.4 Dongcheng Radiopharmaceutical (Oral Route) Product Portfolio
  72. 8.12.5 Dongcheng Recent Developments
  73. 8.13 China Isotope & Radiation
  74. 8.13.1 China Isotope & Radiation Company Information
  75. 8.13.2 China Isotope & Radiation Business Overview
  76. 8.13.3 China Isotope & Radiation Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  77. 8.13.4 China Isotope & Radiation Radiopharmaceutical (Oral Route) Product Portfolio
  78. 8.13.5 China Isotope & Radiation Recent Developments
  79. 8.14 Bracco Imaging
  80. 8.14.1 Bracco Imaging Company Information
  81. 8.14.2 Bracco Imaging Business Overview
  82. 8.14.3 Bracco Imaging Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  83. 8.14.4 Bracco Imaging Radiopharmaceutical (Oral Route) Product Portfolio
  84. 8.14.5 Bracco Imaging Recent Developments
  85. 8.15 Advanced Accelerator Applications
  86. 8.15.1 Advanced Accelerator Applications Company Information
  87. 8.15.2 Advanced Accelerator Applications Business Overview
  88. 8.15.3 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Sales, Price, Revenue and Gross Margin (2021-2026)
  89. 8.15.4 Advanced Accelerator Applications Radiopharmaceutical (Oral Route) Product Portfolio
  90. 8.15.5 Advanced Accelerator Applications Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 Radiopharmaceutical (Oral Route) Value Chain Analysis
  2. 9.1.1 Radiopharmaceutical (Oral Route) Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 Radiopharmaceutical (Oral Route) Production Mode & Process
  6. 9.2 Radiopharmaceutical (Oral Route) Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 Radiopharmaceutical (Oral Route) Distributors
  9. 9.2.3 Radiopharmaceutical (Oral Route) Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources
    8. 11.6 Disclaimer

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $3,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst